The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells-Reference-Cited by-同舟云学术

The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells

Published:2018-10-17 Issue:2 Volume:97 Page:152-164
ISSN:0818-9641
Container-title:Immunology and Cell Biology
language:en
Short-container-title:Immunol Cell Biol

Author:

Lepletier Ailin¹,Lutzky Viviana P¹,Mittal Deepak¹,Stannard Kimberley¹,Watkins Thomas S¹²,Ratnatunga Champa N¹²³,Smith Corey¹,McGuire Helen M⁴⁵^ORCID,Kemp Roslyn A⁶^ORCID,Mukhopadhyay Pamela¹,Waddell Nicola¹,Smyth Mark J¹^ORCID,Dougall William C¹,Miles John J¹²³⁷⁸

Affiliation:

1. QIMR Berghofer Medical Research Institute; Brisbane QLD 4006 Australia

2. Faculty of Medicine; The University of Queensland; Brisbane QLD 4029 Australia

3. Centre for Biodiscovery and Molecular Development of Therapeutics; AITHM; James Cook University; Cairns QLD 4870 Australia

4. Discipline of Pathology; School of Medical Sciences; Faculty of Medicine and Health; University of Sydney; Sydney NSW 2006 Australia

5. Ramaciotti Facility for Human Systems Biology; University of Sydney; Sydney NSW 2006 Australia

6. Department of Microbiology and Immunology; University of Otago; Dunedin 9010 New Zealand

7. Division of Infection and Immunity; Cardiff University School of Medicine; Cardiff CF14 4XN UK

8. Medicine, Dentistry and Health; Griffith University; Brisbane QLD 4111 Australia

Funder

National Health and Medical Research Council of Australia

Senior Principal Research Fellowship

NH&MRC Career Development Fellowship

New Zealand Society for Oncology

Roche Translational Cancer Research Fellowship

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/imcb.12205/fullpdf

Reference32 articles.

1. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

2. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial;Hodi;Lancet Oncol,2016

3. Molecular pathways: targeting CD96 and TIGIT for Cancer Immunotherapy;Blake;Clin Cancer Res,2016

4. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors;Gilfillan;J Exp Med,2008

5. Accelerated tumor growth in mice deficient in DNAM-1 receptor;Iguchi-Manaka;J Exp Med,2008

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A shotgun proteomic dataset of human mucosal-associated invariant T cells;Data in Brief;2024-10

2. The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy;Frontiers in Immunology;2024-08-02

3. CD155 as an emerging target in tumor immunotherapy;International Immunopharmacology;2024-04

4. Integrative temporal multi-omics reveals uncoupling of transcriptome and proteome during human T cell activation;npj Systems Biology and Applications;2024-02-28

5. Study protocol for improving mental health during pregnancy: a randomized controlled low-intensity m-health intervention by midwives at primary care centers;BMC Nursing;2023-09-07